Loading...
Loading...
TVTX| Name | Value |
|---|---|
| Revenues | 41.4M |
| Cost of Revenue | 1.5M |
| Gross Profit | 39.9M |
| Operating Expense | 178.8M |
| Operating I/L | -139.2M |
| Other Income/Expense | 3.2M |
| Interest Income | 6.0M |
| Pretax | -135.8M |
| Income Tax Expense | 0.2M |
| Net Income/Loss | -136.1M |
Travere Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of therapies for rare diseases. The company's portfolio includes marketed products such as Chenodal, Cholbam, and Thiola for the treatment of various rare conditions. Additionally, it has promising product candidates like Sparsentan and TVT-058 in advanced clinical trials. Travere Therapeutics also collaborates with research institutions and patient advocacy organizations to identify potential therapeutics for rare diseases. The company's revenue is generated through the sales of its marketed products and potential future commercialization of its product candidates.
